Skip to content
    Clinical Trials

    Cost-Effectiveness of Dato-DXd vs Chemotherapy in Advanced Triple-Negative Breast Cancer

    Xiang et alFrontiers in pharmacology

    Cost-Effectiveness of Dato-DXd vs Chemotherapy in Advanced Triple-Negative Breast Cancer
    A pharmacoeconomic analysis evaluated the cost-effectiveness of first-line datopotamab deruxtecan (Dato-DXd) versus chemotherapy for patients with untreated advanced triple-negative breast cancer who are ineligible for immunotherapy, using data from the phase III TROPION-Breast02 trial. A three-state partitioned survival model was constructed over a 10-year time horizon with 21-day cycles from both United States and Chinese healthcare system perspectives, using willingness-to-pay thresholds of $150,000/QALY and $27,906/QALY, respectively.
    In the United States base-case analysis, Dato-DXd increased overall costs by $565,572.29 and yielded an additional 0.44 QALYs compared with chemotherapy, resulting in an ICER of $1,287,001.65/QALY. In China, Dato-DXd increased costs by $39,052.50 and added 0.42 QALYs, producing an ICER of $92,640.82/QALY. Based on these findings, Dato-DXd was not cost-effective under base-case assumptions in either healthcare setting.
    One-way sensitivity analyses revealed that progression-free survival utility and the drug acquisition price of Dato-DXd were the most influential drivers of model uncertainty. Exploratory scenario analyses indicated that limiting treatment duration to the reported median rendered Dato-DXd cost-effective in both nations. Additionally, modeling a hypothetical dose reduction from 6 mg/kg to 4 mg/kg—assuming unchanged efficacy—achieved cost-effectiveness in China but failed to do so in the United States. The authors concluded that price reductions or modified treatment strategies could improve economic value, contingent upon clinical confirmation of maintained efficacy and acceptable safety.

    Key Takeaways

    • In the base-case analysis, datopotamab deruxtecan generated an incremental cost-effectiveness ratio of $1,287,001.65 per QALY gained in the United States and $92,640.82 per QALY gained in China, exceeding respective willingness-to-pay thresholds of $150,000/QALY and $27,906/QALY.
    • Price reductions of approximately 62.43% in the United States and 28.83% in China are required for datopotamab deruxtecan to achieve cost-effectiveness compared with chemotherapy under base-case assumptions.
    Read the original sourceFrontiers in pharmacology